• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Picard Medical Inc.

    11/13/25 4:15:17 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care
    Get the next $PMI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Picard Medical, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    740459102

    (CUSIP Number)


    08/11/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    740459102


    1Names of Reporting Persons

    Sindex SSI Lending, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,943,585.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,943,585.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,943,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  This percentage is calculated based on 73,701,176 shares of Common Stock of the Issuer issued and outstanding as of September 16, 2025.


    SCHEDULE 13G

    CUSIP No.
    740459102


    1Names of Reporting Persons

    Versa Capital Fund III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,943,585.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,943,585.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,943,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  This percentage is calculated based on 73,701,176 shares of Common Stock of the Issuer issued and outstanding as of September 16, 2025.


    SCHEDULE 13G

    CUSIP No.
    740459102


    1Names of Reporting Persons

    Versa FGP-III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,943,585.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,943,585.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,943,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  This percentage is calculated based on 73,701,176 shares of Common Stock of the Issuer issued and outstanding as of September 16, 2025.


    SCHEDULE 13G

    CUSIP No.
    740459102


    1Names of Reporting Persons

    Versa UGP-III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,943,585.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,943,585.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,943,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  This percentage is calculated based on 73,701,176 shares of Common Stock of the Issuer issued and outstanding as of September 16, 2025.


    SCHEDULE 13G

    CUSIP No.
    740459102


    1Names of Reporting Persons

    Versa Capital Group, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,943,585.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,943,585.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,943,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  This percentage is calculated based on 73,701,176 shares of Common Stock of the Issuer issued and outstanding as of September 16, 2025.


    SCHEDULE 13G

    CUSIP No.
    740459102


    1Names of Reporting Persons

    Gregory L. Segall
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,943,585.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,943,585.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,943,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  This percentage is calculated based on 73,701,176 shares of Common Stock of the Issuer issued and outstanding as of September 16, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Picard Medical, Inc.
    (b)Address of issuer's principal executive offices:

    1992 E Silverlake, Tucson, AZ 85713
    Item 2. 
    (a)Name of person filing:

    (1) Sindex SSI Lending, LLC, a Delaware limited liability company ("Sindex") (2) Versa Capital Fund III, L.P., a Delaware limited partnership ("CF III") (3) Versa FGP-III, L.P., a Delaware limited partnership ("FGP-III") (4) Versa UGP-III, LLC, a Delaware limited liability company ("UGP-III") (5) Versa Capital Group, LLC, a Delaware limited liability company ("Versa") (6) Gregory L. Segall, an individual ("Mr. Segall" and, together with Sindex, CF III, FGP III, UGP III, and Versa, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    c/o Versa Capital Management, LLC 130 N. 18th Street Suite 315 Philadelphia, PA 19103
    (c)Citizenship:

    Mr. Segall is a citizen of the United States. The other Reporting Persons were formed under the laws of the State of Delaware.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    740459102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Sindex SSI Lending, LLC: 7,943,585 shares of Common Stock Versa Capital Fund III, L.P.: 7,943,585 shares of Common Stock Versa FGP-III, L.P.: 7,943,585 shares of Common Stock Versa UGP-III, LLC: 7,943,585 shares of Common Stock Versa Capital Group, LLC: 7,943,585 shares of Common Stock Gregory L. Segall: 7,943,585 shares of Common Stock
    (b)Percent of class:

    Sindex SSI Lending, LLC: 10.8% Versa Capital Fund III, L.P.: 10.8% Versa FGP-III, L.P.: 10.8% Versa UGP-III, LLC: 10.8% Versa Capital Group, LLC: 10.8% Gregory L. Segall: 10.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Sindex SSI Lending, LLC: 7,943,585 Versa Capital Fund III, L.P.: 7,943,585 Versa FGP-III, L.P.: 7,943,585 Versa UGP-III, LLC: 7,943,585 Versa Capital Group, LLC: 7,943,585 Gregory L. Segall: 7,943,585

     (ii) Shared power to vote or to direct the vote:

    Sindex SSI Lending, LLC: 0 Versa Capital Fund III, L.P.: 0 Versa FGP-III, L.P.: 0 Versa UGP-III, LLC: 0 Versa Capital Group, LLC: 0 Gregory L. Segall: 0

     (iii) Sole power to dispose or to direct the disposition of:

    Sindex SSI Lending, LLC: 7,943,585 Versa Capital Fund III, L.P.: 7,943,585 Versa FGP-III, L.P.: 7,943,585 Versa UGP-III, LLC: 7,943,585 Versa Capital Group, LLC: 7,943,585 Gregory L. Segall: 7,943,585

     (iv) Shared power to dispose or to direct the disposition of:

    Sindex SSI Lending, LLC: 0 Versa Capital Fund III, L.P.: 0 Versa FGP-III, L.P.: 0 Versa UGP-III, LLC: 0 Versa Capital Group, LLC: 0 Gregory L. Segall: 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sindex SSI Lending, LLC
     
    Signature:/s/ Randall Schultz
    Name/Title:Randall Schultz, as Attorney-in-Fact for: Sindex SSI Lending, LLC (1)
    Date:11/13/2025
     
    Versa Capital Fund III, L.P.
     
    Signature:/s/ Randall Schultz
    Name/Title:Randall Schultz, as Attorney-in-Fact for: Versa Capital Fund III, L.P. (1)
    Date:11/13/2025
     
    Versa FGP-III, L.P.
     
    Signature:/s/ Randall Schultz
    Name/Title:Randall Schultz, as Attorney-in-Fact for: Versa FGP-III, L.P. (1)
    Date:11/13/2025
     
    Versa UGP-III, LLC
     
    Signature:/s/ Randall Schultz
    Name/Title:Randall Schultz, as Attorney-in-Fact for: Versa UGP-III, LLC (1)
    Date:11/13/2025
     
    Versa Capital Group, LLC
     
    Signature:/s/ Randall Schultz
    Name/Title:Randall Schultz, as Attorney-in-Fact for: Versa Capital Group, LLC (1)
    Date:11/13/2025
     
    Gregory L. Segall
     
    Signature:/s/ Randall Schultz
    Name/Title:Randall Schultz, as Attorney-in-Fact for: Gregory L. Segall (1)
    Date:11/13/2025

    Comments accompanying signature:  (1) A Power of Attorney authorizing Randall Schultz to act on behalf of this entity or individual is filed as Exhibit 2.
    Exhibit Information

    Exhibit 1 - Joint Filing Agreement Exhibit 2 - Power of Attorney

    Get the next $PMI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sindex Ssi Lending, Llc claimed ownership of 7,943,585 shares (SEC Form 3)

    3 - Picard Medical, Inc. (0002030617) (Issuer)

    11/13/25 4:15:36 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    SEC Filings

    View All

    Picard Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    11/14/25 7:15:37 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Picard Medical Inc.

    10-Q - Picard Medical, Inc. (0002030617) (Filer)

    11/14/25 7:00:54 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Picard Medical Inc.

    SCHEDULE 13G - Picard Medical, Inc. (0002030617) (Subject)

    11/13/25 4:15:17 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Picard Reports Third Quarter 2025 Financial Results

    – Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., commented, "The third quarter marked a pivotal moment for the company with the successful completion of its initial public offering in September. The IPO strengthened the balance sheet by retiring conv

    11/14/25 7:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City

    TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., will be available for one-on-one meetings with investors; to schedule a meeting, please contact your CG sale representative to set up a meeting with management. About Picard Medical and SynCardia Picard Me

    11/12/25 8:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard to Showcase its Total Artificial Heart at the Annual Meeting of the American Heart Association 2025

    TUCSON, Ariz., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced it will exhibit at the annual meeting of the American Heart Association (AHA) being held November 7th through 10th in New Orleans, Louisiana. At the annual meeting of the AHA, Picard will showcase its SynCardia™ Total Artificial Heart (or "STAH"), which is the most widely used and extensively studied artificial heart in the world, at booth #3408. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc. commented, "We a

    11/3/25 8:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care